Head to head
PeterMD vs Maximus
What each one charges a month, which pharmacy each will name, and where each will treat you — read off their own sites, not their marketing.
Both sell compounded tirzepatide — see both on our full tirzepatide list.
What each actually charges
A blank means that provider does not sell that treatment. Read each provider's cost details for the medication, commitment and additional fees behind the listed figure.
| Treatment |  |  |
|---|---|---|
| Tirzepatide | $249/mo (billed quarterly) | $249.99/mo (2-mo prepay) |
| Sermorelin | $211.65 / 4 wks (about $230/mo) | $299.99/mo |
| Brand-name GLP-1 | Doesn't sell it | From $299.99/mo |
| Pharmacy category | Not disclosed | Not disclosed |
PeterMD checked October 2026; Maximus checked October 2026.
Who each one suits
Good fit if you want named pharmacies with street addresses in the Terms.
The catch: The $249 tirzepatide rate is billed quarterly, so the real charge is about $747 every three months after a $149 first payment, and nothing is refundable once it ships. The card says "billed quarterly" on the same line, but in small type under the larger $149.
Good fit if you want sermorelin without lab work.
The catch: Compounded tirzepatide cannot be bought one month at a time. Every plan is prepaid, the shortest is two months ($499.98), and its checkout refund policy gives no refund on a multi-month plan once the first month's supply arrives; changes need 48 hours' notice before the next processing date. The headline prices on its pages are longer-plan or first-month rates, and its company-information page still lists a semaglutide protocol and all-50-state GLP-1 coverage that its product pages and intake no longer show. A live FDA warning letter is on record: Maximus Health, Inc. dba Maximus, MARCS-CMS 730095, June 8, 2026, for claims ("Clinically studied ingredients," "Proven to lose weight effectively") implying FDA evaluation, plus a false "FDA approved pharmacies" claim FDA directly rejects ("Compounding facilities... are not 'FDA-approved' or 'FDA-licensed' entities"). None of those phrases is on its current product pages.
Where each one will treat you
PeterMD
Every state but two for tirzepatide and sermorelin: its pages say "Not available in these states: AL, ID." NAD+ also excludes Louisiana.
Maximus
Tirzepatide: "all states but AL, MS, LA," per its product FAQ, though its company-information page says GLP-1 programs reach all 50 states and DC. Sermorelin: "all states except Alabama."
Ready to start with one?
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.